Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …

Background Renin–angiotensin system (RAS) inhibitors—including angiotensin-converting–
enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs)—slow the progression …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Despite guideline recommendations and available evidence, implementation of treatment in
heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses …

Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

Background: Sodium-glucose cotransporter-2 inhibitors improve heart failure–related
outcomes. The mechanisms underlying these benefits are not well understood, but diuretic …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …